Bilateral versus unilateral cases of chronic rhinosinusitis with nasal polyps have notable clinical and laboratory ...

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

THURSDAY, Feb. 6, 2025 (HealthDay News) -- A few baseline characteristics can predict the need for recurrent endoscopic sinus ...

Oxidative stress plays a critical role in the pathogenesis of upper and lower respiratory tract diseases, such as chronic rhinosinusitis with nasal polyps (CRSwNP), allergic rhinitis (AR), and asthma ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

The following is a summary of “Unveiling the Prevalence and Impact of Silent Rhinovirus Infection in Chronic Rhinosinusitis with Nasal Polyps,” published in the January 2025 issue of Annals of Allergy ...

13 CRSwNP is a chronic condition that affects up to 4% of the general population, of whom 40% have uncontrolled disease. 8,9,12 Depemokimab is currently not approved in any country. The phase III ...

CRSwNP affects up to 4% of the general population, with approximately 40% having uncontrolled disease. In Japan, about 200,000 people with chronic sinusitis are subject to surgery due to nasal polyps.

(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, have been accepted for review in China ...